Citadel Advisors LLC Takes Position in Seaport Therapeutics, Inc. $SPTX

Citadel Advisors LLC acquired a new stake in shares of Seaport Therapeutics, Inc. (NASDAQ:SPTX) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 191,144 shares of the company’s stock, valued at approximately $4,152,000. Citadel Advisors LLC owned 0.36% of Seaport Therapeutics as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. TRV GP VI LLC purchased a new stake in Seaport Therapeutics during the second quarter worth $44,769,742. Alyeska Investment Group L.P. purchased a new position in shares of Seaport Therapeutics in the 2nd quarter valued at $1,629,000. Braidwell LP purchased a new position in shares of Seaport Therapeutics in the 2nd quarter valued at $10,860,000. Finally, HighTower Advisors LLC bought a new position in shares of Seaport Therapeutics in the 2nd quarter worth $362,000.

Analysts Set New Price Targets

A number of brokerages recently weighed in on SPTX. BNP Paribas Exane cut Seaport Therapeutics to a “market perform” rating in a research note on Tuesday, May 26th. UBS Group lowered Seaport Therapeutics to a “sell” rating in a research note on Tuesday, June 9th. JonesTrading began coverage on shares of Seaport Therapeutics in a report on Wednesday, August 26th. They issued a “buy” rating and a $32.00 target price for the company. Zacks Research raised shares of Seaport Therapeutics to a “hold” rating in a research report on Wednesday, May 27th. Finally, Citigroup initiated coverage on shares of Seaport Therapeutics in a report on Tuesday, May 26th. They issued a “buy” rating and a $35.00 price target on the stock. Six analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $37.33.

Insider Activity

In related news, Director Robert Hombach acquired 13,000 shares of the firm’s stock in a transaction that occurred on Monday, June 22nd. The stock was purchased at an average cost of $18.14 per share, with a total value of $235,820.00. Following the transaction, the director directly owned 13,000 shares of the company’s stock, valued at $235,820. This trade represents a ? increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Seaport Therapeutics Stock Performance

Shares of SPTX stock opened at $24.86 on Tuesday. Seaport Therapeutics, Inc. has a 1-year low of $14.85 and a 1-year high of $28.38. The stock’s fifty day simple moving average is $22.34. The stock has a market cap of $1.33 billion and a P/E ratio of -2.05.

Seaport Therapeutics (NASDAQ:SPTX) last released its quarterly earnings results on Monday, August 3rd. The company reported ($1.78) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($1.07). Sell-side analysts predict that Seaport Therapeutics, Inc. will post -4.6 EPS for the current year.

Seaport Therapeutics Company Profile

Seaport Therapeutics Inc is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety and other debilitating neuropsychiatric disorders. Seaport Therapeutics Inc is based in BOSTON.